Abstract

PHAMCOLOGICAL STUDY OF REMDESIVIR ON COVID-19

Prof. Miss Aswini D. Pagare, *Miss. Gauri Vitthal More, Miss. Gayatri Santosh Kotkar, Miss. Gayatri Santosh Khairnar, Mr. Rohit Babasaheb Goyekar

.

Abstract

Remdesivir (Veklury®), a nucleotide analogue prodrug with broadspectrum antiviral activity, is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 infection. Unlike some antivirals, remdesivir has a low potential for drug-drug interactions. In the pivotal ACTT-1 trial in hospitalized patients with COVID-19, daily intravenous infusions of remdesivir significantly reduced time to recovery relative to placebo. Subsequent trials provided additional support for the efficacy of remdesivir in hospitalized patients with moderate or severe COVID-19, with a greater benefit seen in patients with minimal oxygen requirements at baseline. Clinical trials also demonstrated the efficacy of remdesivir in other patient populations, including outpatients at high risk for progression to severe COVID-19, as well as hospitalized paediatric patients. In terms of mortality, results were equivocal. However, remdesivir appeared to have a small mortality benefit in hospitalized patients who were not already being ventilated at baseline. Remdesivir was generally well tolerated in clinical trials, but pharmacovigilance data found an increased risk of hepatic, renal and cardiovascular adverse drug reactions in the real-world setting. In conclusion, remdesivir represents a useful treatment option for patients with COVID-19, particularly those who require supplemental oxygen.

Keywords: Remdesivir, Coronavirus disease 2019, Severe acute respiratory syndrome, coronavirus 2, Antiviral, Variants.